# Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

> **NCT03887026** · PHASE2 · COMPLETED · sponsor: **Emergo Therapeutics, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Allergic Rhinitis
- Allergic Rhinoconjunctivitis

## Interventions

- **DRUG:** Norketotifen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03887026
- **Lead sponsor:** Emergo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2019-05-18
- **Final completion:** 2019-05-29
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03887026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03887026, "Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03887026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*